Business context and reporting period
Senti Biosciences Holdings, Inc. filed this Form 8-K to report results of its reconvened virtual 2026 Annual Meeting, held October 15, 2026, after adjournment from October 8. The filing reports stockholder votes, not quarterly or annual financial results.
Key financial information
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics. It reports approval for issuance of more than 19.99% of the Company’s outstanding common shares upon exchange of Senti Holdings, Inc.’s senior secured convertible notes; it does not state the resulting share count or dilution.
Meeting results and material developments
- Stockholders elected Timothy Lu, M.D., Ph.D., Edward Mathers, and Frances D. Schulz as Class I directors, to serve until the 2029 annual meeting and until successors are qualified.
- Stockholders ratified KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Stockholders approved the issuance of more than 19.99% of outstanding common shares upon exchange of Midco’s senior secured convertible notes: 19,763,523 votes for and 337,042 against.
- Stockholders approved the merger agreement and contemplated transactions. The proposal received 15,851,146 votes for and 4,325,620 against for stockholder approval, and 6,074,146 votes for and 4,325,620 against for majority-of-the-minority approval.
- Stockholders approved a charter amendment authorizing a reverse split at a ratio from 1-for-20 to 1-for-50, at the Board’s discretion and subject to its authority to abandon the amendment. The vote was 19,738,507 for and 451,219 against.
- 20,240,055 of 31,145,390 eligible shares were represented, approximately 64.98%. A proposed adjournment vote was not presented because the required merger votes had been obtained.
Outlook, risks, and unusual items
The filing provides no financial guidance or management outlook. The merger vote and approvals do not, by themselves, establish that the merger has closed. The reverse-split ratio remains subject to Board discretion, and the Board may abandon the amendment. The filing does not provide the merger’s expected closing date, remaining conditions, or the convertible notes’ detailed conversion terms.
Important facts for investors to verify
- Whether the merger closes and whether any conditions or approvals remain outstanding.
- The final reverse-split ratio, timing, and whether the Board elects to proceed.
- The convertible notes’ conversion terms and potential share dilution.
- The merger agreement and proxy statement for transaction terms and additional details.